Arrowhead (ARWR) announced that it has dosed the first subject in the YOSEMITE Phase 3 clinical trial of zodasiran, the company’s investigational RNA interference therapeutic being developed as a potential treatment for homozygous familial hypercholesterolemia. Zodasiran is the fourth investigational RNAi-based candidate developed by Arrowhead to reach late-stage pivotal studies, after investigational drugs plozasiran, fazirsiran and olpasiran.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead completes enrollment in SHASTA-3, SHASTA-4 and MUIR-3
- Arrowhead initiates Phase 1/2a study of ARO-ALK7
- Arrowhead Pharmaceuticals: Strong Buy Rating Backed by Promising RNAi Pipeline and Strategic Partnerships
- Arrowhead Pharmaceuticals’ Earnings Call Highlights Growth and Challenges
- Biotech Alert: Searches spiking for these stocks today